A proof of concept, single centre, monotherapy, dose-ranging trial to evaluate the efficacy and tolerability of CB0011 at 0,7.5, 15, 30 and 45mg in Obstructive Sleep Apnea.
Phase of Trial: Phase I/II
Latest Information Update: 17 Jun 2016
At a glance
- Drugs CB 0011 (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Cypress Bioscience
- 29 Aug 2011 Status changed from active, no longer recruiting to completed as reported by Australian New Zealand Clinical Trials Registry Record.
- 26 Jul 2011 New trial record